目的 探討藤黃健骨聯(lián)合洛索洛芬鈉治療膝骨關(guān)節(jié)炎的臨床療效和安全性。方法 選取2016年6月—2017年6月在河南省洛陽正骨醫(yī)院診治膝骨關(guān)節(jié)炎患者152例，隨機(jī)分成對照組（76例）和治療組（76例）兩組。對照組患者口服洛索洛芬鈉片，1片/次，3次/d；治療組患者在對照組基礎(chǔ)上口服藤黃健骨丸，1丸/次，2次/d。兩組患者均連續(xù)治療6周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者骨關(guān)節(jié)炎指數(shù)、KSS評分和15 m行走時(shí)間，血清白細(xì)胞介素-1β（IL-1β）、軟骨寡聚基質(zhì)蛋白（COMP）和前列腺素E2（PGE2）水平及不良反應(yīng)。結(jié)果 治療后，對照組臨床有效率為86.84%，顯著低于治療組的97.37%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者骨關(guān)節(jié)炎指數(shù)和15 m行走時(shí)間均顯著下降（P<0.05），KSS評分顯著升高（P<0.05），且治療組患者骨關(guān)節(jié)炎指數(shù)、KSS評分和15 m行走時(shí)間均明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者血清IL-1β、COMP和PGE2水平均顯著下降（P<0.05），且治療組患者血清IL-1β、COMP和PGE2水平明顯低于對照組（P<0.05）。治療期間，治療組藥物不良反應(yīng)發(fā)生率為2.63%，顯著低于對照組的13.16%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 藤黃健骨聯(lián)合洛索洛芬鈉治療膝骨關(guān)節(jié)炎療效顯著、安全性高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy and safety of Tenghuang Jiangu Pills combined with loxoprofen sodium in treatment of knee osteoarthritis. Methods Patients (152 cases) with knee osteoarthritis in Luoyang Orthopedic Hospital of Henan Pprovince from June 2016 to June 2017 were randomly divided into control (76 cases) and treatment (76 cases) groups. Patients in the control group were po administered with Loxoprofen Sodium Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Tenghuang Jiangu Pills on the basis of the control group, 1 pill/time, twice daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the osteoarthritis indexes, KSS scores, 15 m walking time, serum IL-1β, COMP and PGE2 levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 86.84%, which was significantly lower than 97.37% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the osteoarthritis indexes and 15 m walking time in two groups were significantly decreased (P<0.05), but KSS scores were significantly increased (P<0.05), and these indicators in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the IL-1β, COMP and PGE2 levels in two groups were significantly decreased (P<0.05), and the serum IL-1β, COMP and PGE2 levels in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 2.63%, which was significantly lower than 13.16% in the control group, with significant difference between two groups (P<0.05). Conclusion Tenghuang Jiangu Pills combined with loxoprofen sodium in treatment of knee osteoarthritis has significant curative effect with less adverse reactions, which has a certain clinical application value.